NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $4.21 -0.06 (-1.41%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$4.21 0.00 (0.00%) As of 06/3/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atea Pharmaceuticals Stock (NASDAQ:AVIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atea Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.16▼$4.3150-Day Range$4.10▼$5.9752-Week Range$2.78▼$6.45Volume330,215 shsAverage Volume351,087 shsMarket Capitalization$336.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization. Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.AI Generated. May Contain Errors. Read More Atea Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreAVIR MarketRank™: Atea Pharmaceuticals scored higher than 20% of companies evaluated by MarketBeat, and ranked 800th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingAtea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAtea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Atea Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.93) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.59% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 19.73, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 1.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.04 News SentimentAtea Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for AVIR on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVIR Stock News HeadlinesAtea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV CatalystMay 29, 2026 | seekingalpha.comAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of ...May 28, 2026 | markets.businessinsider.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears. | Brownstone Research (Ad)Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026May 27, 2026 | globenewswire.comHere's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn SituationMay 20, 2026 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 14, 2026 | finance.yahoo.comAtea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026May 13, 2026 | quiverquant.comQAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis PipelineMay 13, 2026 | globenewswire.comSee More Headlines AVIR Stock Analysis - Frequently Asked Questions How have AVIR shares performed this year? Atea Pharmaceuticals' stock was trading at $3.57 at the beginning of 2026. Since then, AVIR stock has increased by 17.9% and is now trading at $4.21. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. Read the conference call transcript. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $288 million in an IPO on Friday, October 30th 2020. The company issued 12,500,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. Who are Atea Pharmaceuticals' major shareholders? Top institutional investors of Atea Pharmaceuticals include BML Capital Management LLC (8.82%), Dimensional Fund Advisors LP (1.57%), Renaissance Technologies LLC (1.46%) and Irenic Capital Management LP (0.38%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Franklin M Berger, Bruce Polsky and Wayne Foster. View institutional ownership trends. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atea Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO). Company Calendar Last Earnings5/12/2026Today6/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, AVIR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVIR CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees70Year Founded2014Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$158.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.01% Return on Assets-51.49% Debt Debt-to-Equity RatioN/A Current Ratio7.89 Quick Ratio7.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book1.19Miscellaneous Outstanding Shares80,030,000Free Float62,741,000Market Cap$336.93 million OptionableOptionable Beta0.32 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:AVIR) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredAI breakthrough hidden inside SpaceX exposed on June 11On June 11, SpaceX is hosting a major investor event - and growth investor Louis Navellier believes Elon Musk ...InvestorPlace | SponsoredJon Najarian’s Important SpaceX PREDICTIONMost investors are focused on SpaceX's projected June 12 IPO date - but they may be missing the bigger story h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
